Here, we used Ba/F3 cell models of NSCLC driven by uncommon EGFR mutations to evaluate the efficacy of conventional TKIs and novel 3G-TKIs in the first-line setting and the second line after afatinib or osimertinib treatment failure. Here, EGFR is linked to non-small cell lung carcinoma.